Khan R, Raza S, Schreurs N, Xiaoyu W, Hongbao W, Ullah I, et al
25 Jul 2026 at 6:08pm Breaking News
14.3 Weight Reduction and Long-term Maintenance Study of WEGOVY Injection in Pediatric Patients Aged 12 Years and Older with Obesity Overview of Clinical Trial in Pediatric Patients WEGOVY injection was evaluated to reduce excess body weight in pediatric patients aged 12 years of age and older with obesity in a 68-week, double-blind, randomized, parallel group, placebo-controlled, multi-center trial in 201 pubertal pediatric patients aged 12 years and older with BMI corresponding to 95th percentile standardized for age and sex (Study 10) (NCT#04102189)
Beyond aiding in weight management, tirzepatide may also support improved insulin sensitivity and anti-inflammatory effects that benefit metabolic health under the supervision of Dr
Clinical Pharmacology & Therapeutics, 57(5), 552-558